Skip to main content

What drugs are contained in the HIV treatment Delstrigo?

Medically reviewed by Judith Stewart, BPharm. Last updated on June 26, 2024.

Official answer

by Drugs.com

Delstrigo is a three-drug combination of doravirine, lamivudine, and tenofovir disoproxil fumarate. It is used for the treatment of HIV-1 infection.

The three drugs contained in Delstrigo are:

Delstrigo is indicated as a complete regimen a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg:

  • with no antiretroviral treatment history, OR
  • to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components.

The recommended dosage of Delstrigo is one tablet taken orally once daily, with or without food in adults and pediatric patients weighing at least 35 kg.

Each tablet contains 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate.

Read next

Descovy vs Truvada: How do they compare for HIV / PrEP?

Truvada and Descovy are both two-drug, antiviral combinations containing emtricitabine and tenofovir for the treatment of HIV-1 infection, and for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection. Descovy contains a newer form of tenofovir called tenofovir alafenamide (TAF) and Truvada contains the original form of tenofovir as tenofovir disoproxil fumarate (TDF). TAF has less toxicities related to bone and kidneys. Continue reading

What is the difference between Vemlidy and Viread?

Vemlidy (tenofovir alafenamide) and Viread (Tenofovir disproxil fumarate) are antiviral medications marketed by Gilead Sciences. They are both prodrugs of tenofovir.

Vemlidy and Viread are similar in terms of their effectiveness, but Vemlidy is effective at a much lower dose than Viread. Less tenofovir ends up in the bloodstream after taking Vemlidy, leading to improved renal and bone laboratory safety parameters compared with Viread.

Vemlidy also has greater plasma stability, enabling it to deliver tenofovir to hepatocytes more efficiently.

Vemlidy and Viread are both used to treat chronic hepatitis B virus (HBV) infection, but Viread is also used in the treatment of human immunodeficiency virus-1 (HIV-1) infection. Continue reading

Can Descovy be used for pre-exposure prophylaxis (PrEP) in HIV?

Yes. The FDA approved Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) in October 2019 to help reduce the risk of HIV-1 infection. Continue reading

Related medical questions

Related support groups